News coverage about Cytosorbents (NASDAQ:CTSO) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cytosorbents earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.854675102303 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
CTSO has been the subject of several research reports. ValuEngine upgraded shares of Cytosorbents from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Maxim Group set a $12.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a research report on Thursday, October 19th. HC Wainwright reissued a “buy” rating and set a $13.00 price objective on shares of Cytosorbents in a research report on Tuesday, November 21st. Finally, B. Riley reissued a “buy” rating and set a $11.25 price objective on shares of Cytosorbents in a research report on Friday, November 10th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $10.45.
Shares of Cytosorbents (NASDAQ:CTSO) remained flat at $$7.00 during mid-day trading on Monday. 65,700 shares of the stock were exchanged, compared to its average volume of 132,961. Cytosorbents has a 1 year low of $3.30 and a 1 year high of $7.05. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.17 and a current ratio of 3.36.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Cytosorbents (CTSO) Stock Price” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/04/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-cytosorbents-ctso-stock-price.html.
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.